Isoprenoids As Mediators of the Biological Effects of Statins

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2002 Aug 7

PMID 12163444

Citations 141

Authors

James K Liao

Affiliations

Soon will be listed here.

Citing Articles

Statins as an Adjunctive Antithrombotic Agent in Thrombotic Antiphospholipid Syndrome: Mechanisms and Clinical Implications.

Bucci T, Menichelli D, Palumbo I, Pastori D, Ames P, Lip G Cells. 2025; 14(5).

PMID: 40072082 PMC: 11899080. DOI: 10.3390/cells14050353.

Exploring Anti-Inflammatory Treatment as Upstream Therapy in the Management of Atrial Fibrillation.

Zheng E, Warchol I, Mejza M, Mozdzan M, Strzeminska M, Bajer A J Clin Med. 2025; 14(3).

PMID: 39941553 PMC: 11818443. DOI: 10.3390/jcm14030882.

Baseline inflammatory status affects the prognostic impact of statins in patients with peripheral arterial disease.

Jujo K, Ueshima D, Abe T, Shimazaki K, Fujimoto Y, Tanaka T Am Heart J Plus. 2024; 47:100481.

PMID: 39559793 PMC: 11570747. DOI: 10.1016/j.ahjo.2024.100481.

The Effect of Statins on Markers of Breast Cancer Proliferation and Apoptosis in Women with In Situ or Early-Stage Invasive Breast Cancer.

Kamal A, Boerner J, Assad H, Chen W, Simon M Int J Mol Sci. 2024; 25(17).

PMID: 39273534 PMC: 11395452. DOI: 10.3390/ijms25179587.

Statins as anti-tumor agents: A paradigm for repurposed drugs.

Tripathi S, Gupta E, Galande S Cancer Rep (Hoboken). 2024; 7(5):e2078.

PMID: 38711272 PMC: 11074523. DOI: 10.1002/cnr2.2078.

References

Goldstein J, Brown M . Regulation of the mevalonate pathway. Nature. 1990; 343(6257):425-30. DOI: 10.1038/343425a0. View

Aikawa M, Rabkin E, Sugiyama S, Voglic S, Fukumoto Y, Furukawa Y . An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 2001; 103(2):276-83. DOI: 10.1161/01.cir.103.2.276. View

Brown B, Zhao X, Sacco D, Albers J . Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993; 87(6):1781-91. DOI: 10.1161/01.cir.87.6.1781. View

. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344(8934):1383-9. View

Libby P . Molecular bases of the acute coronary syndromes. Circulation. 1995; 91(11):2844-50. DOI: 10.1161/01.cir.91.11.2844. View

Kobashigawa J, Katznelson S, Laks H, Johnson J, Yeatman L, Wang X . Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995; 333(10):621-7. DOI: 10.1056/NEJM199509073331003. View

Shepherd J, Cobbe S, Ford I, Isles C, LORIMER A, Macfarlane P . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333(20):1301-7. DOI: 10.1056/NEJM199511163332001. View

Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F . New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 2000; 84(3):413-28. DOI: 10.1016/s0163-7258(99)00045-5. View

Chan K, Andrade S, Boles M, Buist D, Chase G, Donahue J . Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet. 2000; 355(9222):2185-8. DOI: 10.1016/S0140-6736(00)02400-4. View

10.

Laufs U, Endres M, Stagliano N, Amin-Hanjani S, Chui D, Yang S . Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest. 2000; 106(1):15-24. PMC: 314365. DOI: 10.1172/JCI9639. View

11.

Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer D . The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000; 6(9):1004-10. PMC: 2828689. DOI: 10.1038/79510. View

12.

Perez-Sala D, Soria E, Lamas S . Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res. 2000; 87(7):616-22. DOI: 10.1161/01.res.87.7.616. View

13.

Wolozin B, Kellman W, Ruosseau P, CELESIA G, Siegel G . Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000; 57(10):1439-43. DOI: 10.1001/archneur.57.10.1439. View

14.

Jick H, Zornberg G, Jick S, Seshadri S, Drachman D . Statins and the risk of dementia. Lancet. 2000; 356(9242):1627-31. DOI: 10.1016/s0140-6736(00)03155-x. View

15.

Wassmann S, Laufs U, Baumer A, Muller K, Konkol C, Sauer H . Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001; 59(3):646-54. DOI: 10.1124/mol.59.3.646. View

16.

Crisby M, Shah P, Yano J, Zhu J, Nilsson J . Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001; 103(7):926-33. DOI: 10.1161/01.cir.103.7.926. View

17.

McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, SCHNECK D . Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001; 87(5A):28B-32B. DOI: 10.1016/s0002-9149(01)01454-0. View

18.

Schwartz G, Olsson A, Ezekowitz M, Ganz P, Oliver M, Waters D . Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001; 285(13):1711-8. DOI: 10.1001/jama.285.13.1711. View

19.

Illingworth D, Tobert J . HMG-CoA reductase inhibitors. Adv Protein Chem. 2001; 56:77-114. DOI: 10.1016/s0065-3233(01)56003-9. View

20.

Istvan E, Deisenhofer J . Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001; 292(5519):1160-4. DOI: 10.1126/science.1059344. View